Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases. The company is based in the UK with offices at the Sussex Innovation Centre.
- TMEM16A Channel Function Does Not Influence Goblet Cell Numbers or Mucin Secretion In The Human Airway Epithelium – NACFC – Nashville – October 2019November 7, 2019 - 5:32 pm
- EACT Increases Intracellular Calcium Levels by a Tmem16a-Independent Mechanism – NACFC – Nashville – October 2019November 7, 2019 - 5:30 pm
- The In Vitro & In Vivo Pharmacology of Novel Tmem16a Potentiator Compounds – NACFC – Nashville – October 2019November 7, 2019 - 5:29 pm
- Enterprise Therapeutics awarded up to £5.7M ($7M) from Cystic Fibrosis Foundation to Support Clinical Development of Novel Chloride Channel ModulatorOctober 15, 2019 - 9:00 am
Follow Us On Twitter
We'll be kicking off 2020 by attending the annual @jpmorgan healthcare conference. Contact us to arrange a meeting, to learn more about our novel muco-regulatory therapies for #respiratorydisease: http://bit.ly/2DrFEKh #JPM2020